Loading...
Loading...
BLUE| Name | Value |
|---|---|
| Revenues | 16.1M |
| Cost of Revenue | 28.9M |
| Gross Profit | -12.8M |
| Operating Expense | 75.5M |
| Operating I/L | -88.4M |
| Other Income/Expense | 7.0M |
| Interest Income | 2.8M |
| Pretax | -81.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -81.4M |
bluebird bio, Inc. is a biotechnology company specializing in transformative gene therapies for severe genetic diseases. The company's product candidates include betibeglogene autotemcel for transfusion-dependent ß-thalassemia, lovotibeglogene autotemcel for sickle cell disease, and elivaldogene autotemcel for cerebral adrenoleukodystrophy. Its clinical study program evaluates the safety and efficacy of these therapies. bluebird bio, Inc. also has strategic collaboration and license agreements with other biotech companies. The company generates revenue through the research, development, and commercialization of gene therapies for severe genetic diseases.
